Company Overview and News

5
Pershing Square Holdings Ltd. (PSHZF) CEO Bill Ackman on Q2 2018 Results - Earnings Call Transcript

2018-08-15 seekingalpha
Pershing Square Holdings Ltd. (OTCPK:PSHZF) Q2 2018 Earnings Conference Call August 15, 2018 11:00 AM ET
HD THI PSHZF UTX COL HHC MS

28
Tracking Bill Ackman's Pershing Square Portfolio - Q2 2018 Update

2018-08-15 seekingalpha - 2
The largest three 13F positions are Restaurant Brands International, Chipotle Mexican Grill, and Lowes Companies and together they account for ~56% of the portfolio.
LOW PAH ADP THI FNMA QSR.WI FMCKI FMCKJ QSR FMCCO BKW FMCCP FMCCM FMCCN FMCCI FMCCJ FMCCG FMCKO MDLZ UTX PSHZF FMCKP FMCKM FMCKN FMCKK CMG FMCKL HHC FMCC ADPVV FMCCS FMCCT

2
US markets: investors switch focus to earnings; Turkey crisis weighs

2018-08-15 cnbc
U.S. stock index futures came under pressure ahead of Wednesday's open, as investors awaited fresh corporate earnings from major U.S. companies.
CSCO PSHZF

4
As Bill Ackman Proves Himself Almost Cured, David Einhorn Now Showing Symptoms Of Late-Stage Ackmania | Dealbreaker

2018-08-10 dealbreaker
William Ackman’s publicly traded hedge fund is outperforming the broader stock market this year, fueled by rising prices at Chipotle Mexican Grill and Automatic Data Processing Inc, the billionaire investor said on Thursday. “While a few months of strong performance is too short a period to judge our performance, we believe that (Pershing Square Holdings) is back on track,” Ackman wrote in his firm’s interim financial report.
ADPVV ADP PSHZF CMG

5
Ackman's public hedge fund beats market with 12.7 pct gain -report

2018-08-09 reuters - 1
NEW YORK (Reuters) - William Ackman’s publicly traded hedge fund is outperforming the broader stock market this year, fueled by rising prices at Chipotle Mexican Grill and Automatic Data Processing Inc, the billionaire investor said on Thursday.
ADPVV ADP PSHZF CMG

6
Ackman’s Comeback: How to Ride His Revival - Barron's

2018-07-17 barrons - 2
This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.
GLRE TPRE ADP TPOG VRX PSHZF BAX UTX QSR.WI CMG ADPVV TPOU QSR

 
Bill Ackman and Other Pershing Square Capital Management Affiliates Have Acquired More Than $300 Million of PSH Public Shares Since May 2018 | Business Wire

2018-07-10 businesswire
Pershing Square Holdings, Ltd. (“PSH” or the “Company”) (LN:PSH) (NA:PSH) today announces that the Company has been advised by Pershing Square Capital Management, L.P. (“PSCM”) that CEO Bill Ackman, PSH Board Member Nick Botta, all members of the Pershing Square investment team, other PSCM employees and members of the PSCM advisory board (together, the “PSCM Affiliates”) have purchased a total of 20,659,629 PSH public shares since they began acquiring shares subsequent to the 10 May 2018 closure of the $300 million Company Tender Offer.
PSHZF

7
Ackman makes fresh layoffs at Pershing Square hedge fund

2018-06-27 channelnewsasia
BOSTON: Billionaire hedge fund manager William Ackman, whose investment assets have shrunk by more than half in the last three years, has made a second round of staff cuts and laid off three investor relations team members, two sources familiar with the matter said on Tuesday.
NKE UTX PSHZF

7
Exclusive: Ackman makes fresh layoffs at Pershing Square hedge fund - Channel NewsAsia

2018-06-27 channelnewsasia
Billionaire hedge fund manager William Ackman, whose investment assets have shrunk by more than half in the last three years, has made a second round of staff cuts and laid off three investor relations team members, two sources familiar with the matter said on Tuesday.
NKE UTX PSHZF

7
Exclusive: Ackman makes fresh layoffs at Pershing Square hedge fund

2018-06-27 reuters
BOSTON (Reuters) - Billionaire hedge fund manager William Ackman, whose investment assets have shrunk by more than half in the last three years, has made a second round of staff cuts and laid off three investor relations team members, two sources familiar with the matter said on Tuesday.
NKE UTX PSHZF

45
Pershing Square Sends Communication To Investors Regarding ADP – ValueWalk Premium

2018-06-20 valuewalkpremium
Pershing Square Holdings, Ltd. (LN: PSH) (NA: PSH) today released an email sent from Pershing Square Capital Management, L.P. to its investors. The text of the email is set forth below:
ADPVV ADP PSHZF

45
Pershing Square Sends Communication to Investors Regarding ADP | Business Wire

2018-06-20 businesswire
Pershing Square Holdings, Ltd. (LN: PSH) (NA: PSH) today released an email sent from Pershing Square Capital Management, L.P. to its investors. The text of the email is set forth below:
ADPVV ADP PSHZF

36
Ackman Is Back; Time To Back Ackman Via Pershing Square Holdings

2018-06-12 seekingalpha
When celebrity hedge fund manager Bill Ackman appeared on the cover of Forbes in May 2015 as "Baby Buffett" (above), in retrospect it marked his "Sports Illustrated Curse" moment. Over the past three years, Ackman's perfect billionaire life has seemingly imploded, marred by a huge ($1 billion) short bet gone awry (Herbalife (HLF), for which see here), a massive (>$3 billion) long bet gone spectacularly wrong (i.
BRK.A PSHZF IEP

36
Ackman's Back; Time To Back Ackman Via Pershing Square Holdings

2018-06-12 seekingalpha
When celebrity hedge fund manager Bill Ackman appeared on the cover of Forbes in May 2015 as "Baby Buffett" (above), in retrospect it marked his "Sports Illustrated Curse" moment. Over the past three years, Ackman's perfect billionaire life has seemingly imploded, marred by a huge ($1 billion) short bet gone awry (HLF, for which see here), a massive (>$3 billion) long bet gone spectacularly wrong (i.
BRK.A PSHZF IEP

85
Bill Ackman's fund scores second-best month since 2014

2018-06-08 cnbc - 1
Bill Ackman's hedge fund notched a double-digit gain in May, getting a boost from investments like Lowe's, Chipotle Mexican Grill, and Automatic Data Processing.
ADPVV ADP UTX PSHZF CMG

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: G7016V101